The main questions for biotech investors are whether there is a correlation between the price of oil and if there is such a correlation, what is it telling us at the current period and the potential for the price action in the biotech sector? Read More

With all the bad news out there it is sometimes difficult to keep in mind that investor capital never stops chasing opportunity, no matter what the circumstances. Read More

It had to happen sooner or later; after soundly beating the overall market in 2015, the tech sector is now taking its turn under the harsh glare of market scrutiny. As a result, the tech-heavy NASDAQ Composite Index declined 5.5% the first week of February, coming on the heels of… Read More

For the first time since we launched STI over two years the total return for the NASDAQ Composite Index is virtually identical for the trailing one week, four weeks, and twelve months at roughly -0.5%. Read More

There is a widely held belief among technical traders that after testing a support level three times the index must move strongly one direction or the other, either dropping through it on the downside to its previous support level, or zooming up past its previous highs. We will soon find out if it holds true this time. Read More

Wall Street continues to get more bullish on Zendesk (ZEN), provider of a cloud-based customer service platform. Canaccord Genuity early last month named Zendesk a top small-cap pick, saying the company is evolving its business model to a multi-product platform offering from a single solution. The move to an expanded… Read More

After declining 32% in 2015, shares of Qualcomm (QCOM)—a holding in the Investments Portfolio—during the turbulent first two weeks of this year have fallen just over 8%. At these reduced valuation levels, the chip maker offers a lower-risk way to play growth in three key emerging segments of the technology… Read More

In troubled markets, it’s rare to find a company that offers the right mix between safety and potential growth. For 2016, the one stock to own is Novo Nordisk, which became an active EBIS portfolio component on 12/21/15. We didn’t make this choice lightly, especially at a time of rising… Read More

Don't wait until panic over China's currency devaluation has subsided and the stock market recovers another 10 - 20% before taking action, like many amateur investors do. Instead, use this interlude of heightened volatility to acquire companies with excellent long term growth prospects that are getting punished indiscriminately along with the rest of the market.   Read More